CheckMate 816 trial
The CheckMate 816 study has demonstrated that neoadjuvant nivolumab + chemotherapy enhances event-free survival and pathologic complete response when compared to chemotherapy alone in patients with resectable non-small lung cancer. During the ASCO 2023 conference, Prof Dr Jonathan Spicer of the McGill University Health Center in Montreal, Canada shared a poster showcasing the 3-year efficacy and safety outcomes in patients who underwent definitive surgery and those who did not.
With the educational support of:
